Journal profile · Pharmacology, Toxicology and Pharmaceutics-Pharmacology, Toxicology and Pharmaceutics (miscellaneous)
Frontiers in Drug Safety and Regulation
ISSN 2674-0869 · Frontiers Media S.A. · Switzerland
Frontiers in Drug Safety and Regulation: fully open access; APC charged, amount not published; median 99 days to acceptance (54 articles, last 24 months); 28 articles in 2025; indexed in Scopus.
Scope
Aims, scope and focus
Frontiers in Drug Safety and Regulation is published by Frontiers Media S.A.. By OpenAlex counts of its recent articles, its largest topics are Pharmacovigilance and Adverse Drug Reactions, Pharmaceutical industry and healthcare and Healthcare Regulation, together about 44% of its articles. (generated from OpenAlex topic counts and CAS ranking data)
Frontiers in Drug Safety and Regulation is a PubMed Central and Scopus-indexed multidisciplinary journal that aims to address potentially emerging issues concerning pharmacovigilance, with special emphasis on how the post-marketing surveillance drives informed regulatory decision process and vice versa. Led by Field Chief Editor Prof Gianluca Trifirò (University of Verona, Italy), Frontiers in Drug Safety and Regulation publishes epidemiological, clinical and translational original articles, editorials and reviews across the fields of clinical pharmacology, pharmacovigilance, pharmacoepidemiology, drug policy, public health and regulatory science. Topics of interest include: advanced methods in pharmacovigilance and pharmacoepidemiology clinical drug safety maternal-fetal medicine pharmaceutical policy and regulation substance-based medical devices vaccine safety and regulation Drug safety monitoring is an essential element for the effective and safe use of medicines and for high quality medical care and it is the process of detection, assessment, understanding and prevention of side effects, allowing an in-depth knowledge of the benefit-risk profile of conventional drugs and vaccines as well as advanced therapy medicinal products (ATMPs, e.g. gene therapy medicinal products, somatic cell therapy medicinal products, tissue engineered medicinal products, medicinal products for combined advanced therapies,), dietary supplements/nutraceuticals and medical devices. Regulatory science refers to the range of scientific disciplines aimed at assessing the quality, safety and efficacy/effectiveness of medicinal products and informing regulatory decision-making throughout the lifecycle of a medicine. It comprises basic and applied biomedical and social sciences and contributes to the development of regulatory standards and tools. In particular, the journal welcomes submissions which support and advance the UN’s Sustainable Development Goals (SDGs), notably SDG 3: ensure healthy lives and promote well-being for all at all ages. Collaboration between clinicians and basic scientists is strongly encouraged by the editors and papers issued from a collaborative strategy between the academic and the private industrial sectors are welcome. Manuscripts which do not relate to conventional drugs, vaccines, ATMPs, nutraceuticals and dietary supplements or medical devices, as well as isolated in vitro or in vivo studies that are not linked to clinical evaluations, are not suitab
From the journal's Aims & Scope
Research area (LetPub): Pharmacology, Toxicology and Pharmaceutics-Pharmacology, Toxicology and Pharmaceutics (miscellaneous)
Editorial board by country: none in mainland China; most named Italy 8, United States 3, Netherlands 2, Spain 1, Switzerland 1 (17 members with a country) Editorial board ↗Publisher website ·
Main research topics OpenAlex counts of recent articles; shares are approximate
- Pharmacovigilance and Adverse Drug ReactionsPharmacology, Toxicology and Pharmaceutics28.2%
- Pharmaceutical industry and healthcarePharmacology, Toxicology and Pharmaceutics8.5%
- Healthcare RegulationHealth Professions7.3%
- Data-Driven Disease SurveillanceMedicine6.5%
- Pharmaceutical studies and practicesMedicine6.1%
- Statistical Methods in Clinical TrialsMathematics5.2%
- SARS-CoV-2 and COVID-19 ResearchMedicine4%
- Biomedical Ethics and RegulationMedicine4%
Rankings & indexing
CAS ranking and database indexing
CAS Journal Ranking
CAS Journal Ranking, upgraded edition (March 2025)Not covered
Not covered by this edition.
CAS Xinrui Journal Ranking (March 2026)Not covered
Not covered by this edition.
CAS Journal Ranking, previous upgraded edition (December 2023)Not covered
Not covered by this edition.
CiteScore quartiles (Scopus, June 2026 release)
| Subject | Quartile | Rank | Percentile |
|---|---|---|---|
| Pharmacology, Toxicology and Pharmaceutics (miscellaneous) | Q1 | 14/57 | 76th |
| Medicine (miscellaneous) | Q2 | 159/466 | 65th |
| Epidemiology | Q2 | 68/173 | 60th |
| Pharmacology (medical) | Q2 | 136/278 | 51st |
Scopus ranks journals by CiteScore within each subject: the 75th percentile and above is Q1, then a quartile every 25 points. A different system from the CAS zones.LetPub
Database indexing
ScopusDOAJLetPub
International journal early-warning lists: not listed in any editionLetPub
Indexing the journal's website claims
PMCPublisher website
Other: EBSCO, ProQuest, Dimensions, CNKI, CLOCKSS, Crossref
As the journal's website lists them, not checked against each database; for Web of Science editions the records above apply.
Editions, and major and minor categories, are shown separately and never merged into one zone; check which edition your institution uses before you submit or report.
Metrics
Impact metrics and publication volume
Impact
- CiteScore 2026-06
- 4LetPub ·
- CiteScore (publisher)
- 4Publisher website ·
- SJR 2026-06
- 0.72LetPub ·
- SNIP 2026-06
- 0.95LetPub ·
- h-index
- 13OpenAlex ·
- i10-index
- 19OpenAlex ·
- 2-year mean citedness
- 5.56OpenAlex ·
- Share of gold OA articles
- 0%LetPub ·
Articles by year OpenAlex count · 127 in total · the current year is incomplete
| Year | Articles | Open access | Citations |
|---|---|---|---|
| 2026 | 29 | 29 | 355 |
| 2025 | 28 | 28 | 281 |
| 2024 | 22 | 22 | 141 |
| 2023 | 25 | 25 | 60 |
| 2022 | 22 | 22 | 23 |
| 2021 | 1 | 1 | 0 |
Sources count differently and were observed at different times, so each source's own value is kept; "publisher" marks figures from the journal's website.
Review & acceptance
Review time and acceptance
Review time from article dates manuscript dates registered with PubMed · to
97 daysMedian, submission to acceptance · P25–P75 55 days – 123 days
- Acceptance to online
- median 26 days (56 articles)
- Submission to online
- median 120 days
- Sample
- 56 articles with submission and acceptance dates (60 in the window); the latest was accepted on
Only articles that were accepted and published are counted, not the time spent on rejected manuscripts, so this usually runs longer than a publisher's "time to first decision".
Other sources
- Average review time (community reports)
- about 15 weeksLetPub ·
- Submission to publication (journal-reported)
- about 15 weeksDOAJ ·
- Peer review
- Single anonymous peer reviewDOAJ
Community reports come from authors' own submissions (confidence 0.5) and are not a promise from the journal; for publisher figures, the journal's own definitions apply.
Fees & open access
APC and open-access policy
Fully open accessDOAJ
Every article is open access; authors usually pay an article processing charge (APC).
| Source | APC | Fee waiver | License | Observed |
|---|---|---|---|---|
| DOAJ | CHF 1,950 | Yes | CC BY | |
| OpenAlex | CHF 1,950 | — | — | |
| LetPub | USD 2,125 | Yes | — |
The journal's website is authoritative for fees; sources were observed at different times and each keeps its own value, without averaging.
Submission
Article types and submission policies (journal website)
What to prepare2 items from the author guidelines
- Keywords
- 5–8
- Reference style
- Harvard
Policy excerpts from the journal's websiteAI use, Conflicts of interest, License & copyright, Open access, Peer review
- AI use Use of AI to create written or visual content
Authors should not list a generative AI technology as a co-author or author of any submitted manuscript. Generative AI technologies cannot be held accountable for all aspects of a manuscript and consequently do not meet the criteria required for authorship. If the author of a submitted manuscript has used written or visual content produced by or edited using a generative AI technology, this use mu…
Source ↗Publisher website ·- Conflicts of interest Safeguards against financial conflicts of interest
Only leading researchers acting as Associate Editors, who are not part of Frontiers' staff, can make acceptance decisions based on reviews performed by external experts acting as Community Reviewers or Reviewers. None have a financial incentive to accept articles, i.e. they are not paid for their role as Associate Editor or community Reviewer, and any award scheme is not linked to acceptances of m…
Source ↗Publisher website ·- License & copyright Open access and copyright
All Frontiers' articles from July 2012 onwards are published with open access under the Creative Commons CC-BY license (the current version is CC-BY, version 4.0). This means that the author(s) retains copyright, but the content is free to download, distribute, and adapt for commercial or non-commercial purposes, given appropriate attribution to the original article. Upon submission, the author(s)…
Source ↗Publisher website ·- Open access Open access and copyright
APCs apply to articles accepted for publication after peer review. Model summary
All Frontiers' articles from July 2012 onwards are published with open access under the Creative Commons CC-BY license (the current version is CC-BY, version 4.0). This means that the author(s) retains copyright, but the content is free to download, distribute, and adapt for commercial or non-commercial purposes, given appropriate attribution to the original article. Upon submission, the author(s)…
Source ↗Publisher website ·- Peer review Peer review
Peer review process described as rigorous and transparent, combining expert review and constructive dialogue. Model summary
Our rigorous, transparent peer review process combines expert review and constructive dialogue to strengthen your manuscript.
Source ↗Publisher website ·
Excerpts are quoted from the journal's website; "model summary" lines are written by Workers AI and checked against the text. The journal's website is authoritative.
Profile
Publication details and official links
- Publisher
- Frontiers Media S.A.
- Country or region
- Switzerland
- Language
- English
- ISSN
- 2674-0869
- Official links
- Journal homepage ↗LetPub
- Submission system ↗Publisher website
- Author guidelines ↗LetPub
- Aims & Scope ↗LetPub
- Special issues ↗Publisher website
- APC information ↗DOAJ
- Fee waivers ↗DOAJ
- Open access statement ↗DOAJ
- License & copyright ↗DOAJ
- Peer review process ↗LetPub
- Editorial board ↗LetPub
- Plagiarism policy ↗DOAJ
FAQ
Frequently asked questions about Frontiers in Drug Safety and Regulation
How long does peer review take at Frontiers in Drug Safety and Regulation?
Based on the dates recorded on 54 articles published between November 2024 and November 2026 (the last 24 months), the median time from submission to acceptance is 99 days (interquartile range 55–126 days); authors report an average review time of about 15 weeks. Article statistics cover accepted papers only, publisher figures follow the journal's own definitions, and community reports come from authors' own submissions; none is a promise from the journal.
What are the manuscript requirements of Frontiers in Drug Safety and Regulation?
According to the journal's author guidelines: Keywords: 5–8; Reference style: Harvard. A model extracted these from the author guidelines and each was checked against the text; check the latest version on the journal's website before submitting.
Where are the editorial board members of Frontiers in Drug Safety and Regulation based?
Of the 17 board members whose country the journal's board page names, none are in mainland China; the countries named most often are Italy (8), United States (3) and Netherlands (2). Counted from the institutions listed on the board page; for reference only.
Which databases index Frontiers in Drug Safety and Regulation?
According to LetPub and DOAJ records, Frontiers in Drug Safety and Regulation is indexed in Scopus and DOAJ. The journal's website also lists PMC; that list has not been checked against each database.
Is Frontiers in Drug Safety and Regulation open access, and what is the APC?
Frontiers in Drug Safety and Regulation is a fully open-access journal. APC charged, amount not published.
Sources and updates
The facts on this page come from LetPub, OpenAlex, Publisher website, DOAJ; every figure is tagged with its source and the date it was observed, and conflicting values are kept per source. LetPub source page: view ↗ (archived 2026-08-25). Last updated: .